Stock SPRY ARS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

ARS Pharmaceuticals, Inc. Share Price

Equities

SPRY

US82835W1080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 01:30:00 27/04/2024 am IST 		5-day change 1st Jan Change
8.35 USD +3.21% Intraday chart for ARS Pharmaceuticals, Inc. -1.42% +52.37%
18/04 ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
18/04 ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT

Financials

Sales 2024 * 5.54M 462M Sales 2025 * 85.45M 7.12B Capitalization 809M 67.46B
Net income 2024 * -59M -4.92B Net income 2025 * -35M -2.92B EV / Sales 2024 * 120 x
Net cash position 2024 * 141M 11.79B Net cash position 2025 * 144M 12.03B EV / Sales 2025 * 7.78 x
P/E ratio 2024 *
-13.7 x
P/E ratio 2025 *
-24.3 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 72.22%
More Fundamentals * Assessed data

Chart ARS Pharmaceuticals, Inc.

Dynamic Chart

Latest news about ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing MT
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy MT
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy DJ
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray) CI
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index CI
North American Morning Briefing : Stock Futures -2- DJ
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6 MT
ARS Pharmaceuticals Announces neffy Meets Primary Endpoints and Shows Rapid Symptom Control in Phase 2 Urticaria Clinical Study CI
ARS Pharmaceuticals' Repeat Dose Study Shows Epinephrine Nasal Spray as Good as Injection MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform MT
ARS Pharmaceuticals, Inc. Announces Favorable Topline Results from Repeat Dosing Study of neffy (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA?s Complete Response Letter CI
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating MT
More news

Analyst Recommendations on ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing MT
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6 MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform MT
More recommendations

Press releases ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) GL
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray) AQ
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results GL
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day AQ
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day GL
More press releases

News in other languages on ARS Pharmaceuticals, Inc.

Wall Street termine en baisse, la chute du moral des consommateurs pèse
Wall Street ouvre en petite hausse, continue de digérer les derniers indicateurs
More news

Quotes and Performance

1 day+3.21%
1 week-1.42%
Current month-18.30%
1 month-16.50%
3 months+32.86%
6 months+137.22%
Current year+52.37%
More quotes

Highs and lows

1 week
7.66
Extreme 7.66
8.83
1 month
7.66
Extreme 7.66
11.27
Current year
5.19
Extreme 5.19
11.27
1 year
2.55
Extreme 2.55
11.27
3 years
2.55
Extreme 2.55
11.27
5 years
2.55
Extreme 2.55
11.27
10 years
2.55
Extreme 2.55
11.27
More quotes

ETFs positioned on ARS Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares 3x Long Biotechnology ETP Securities - USD
0.01% 0 M€ 0.00% -
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD ETF Leverage Shares -3x Short Biotechnology ETP Securities - USD
0.01% 0 M€ 0.00% -
More ETFs positioned on ARS Pharmaceuticals, Inc.

Quotes

Date Price Change Volume
26/24/26 8.35 +3.21% 520,298
25/24/25 8.09 -2.06% 534,709
24/24/24 8.26 -2.82% 334,679
23/24/23 8.5 +3.53% 510,439
22/24/22 8.21 -3.07% 394,656

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes

Company Profile

ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Sector
Biotechnology & Medical Research
Calendar
13/05/2024 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for ARS Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
8.35 USD
Average target price
19 USD
Spread / Average Target
+127.54%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARS PHARMACEUTICALS, INC. Stock ARS Pharmaceuticals, Inc.
+52.37% 806M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SPRY Stock